GlassScriptPhysician profile
Heather W Murphy
NPI 1568983633
$6,803.64
in general payments reported to CMS, 2019-2025
22 companies · $730 in 2025
The $730 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $919 · 2022: $1,328 · 2023: $3,000 · 2024: $828 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,321 · Consulting Fee: $1,013 · Education: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,321.13 |
| Consulting Fee | $1,012.50 |
| Education | $223.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $1,237.33 | 2023 | Stimufend |
| Glaxosmithkline, LLC. | $932.23 | 2021-2024 | Jemperli, Zejula |
| Daiichi Sankyo INC. | $666.25 | 2022-2025 | Datroway, Enhertu |
| Astrazeneca Pharmaceuticals LP | $498.05 | 2022-2024 | Tagrisso |
| Eisai INC. | $443.20 | 2021-2024 | |
| Gilead Sciences, INC. | $426.44 | 2022-2025 | Trodelvy |
| Stemline Therapeutics INC. | $412.16 | 2023-2024 | Orserdu |
| Tactile Systems Technology INC | $350.94 | 2023-2024 | Flexitouch Plus, Entre Plus |
| Lilly USA, LLC | $307.27 | 2021-2023 | Verzenio |
| Puma Biotechnology, INC. | $278.13 | 2021-2025 | |
| Servier Pharmaceuticals LLC | $242.74 | 2023 | |
| Merck Sharp & Dohme LLC | $205.52 | 2021-2023 | Keytruda, Lynparza |
| Exelixis INC. | $121.08 | 2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $119.37 | 2022 | |
| Mirati Therapeutics, INC. | $112.25 | 2023 | Krazati |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $99.00 | 2023 | |
| Genentech, INC. | $93.41 | 2023-2025 | Phesgo, Itovebi |
| Amgen INC. | $89.22 | 2021 | |
| Genentech USA, INC. | $73.87 | 2022-2023 | Perjeta, Phesgo |
| Ethicon US, LLC | $49.88 | 2022 | |
| Aveo Pharmaceuticals, INC. | $24.87 | 2024 | |
| Geron Corporation | $20.43 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.